-   Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation -   OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional$665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, toda ...